Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2012
已完成
3
30.0%
招募中
6
60.0%
终止
1
10.0%
暂无批准数据
- Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer, effective August 20, 2026, as the company advances its late-stage clinical pipeline and prepares for commercialization. - Mr. Burwell brings more than 20 years of human resources leadership experience in life sciences, including roles at Bolt Biotherapeutics and Global Blood Therapeutics. - The appointment supports Nurix's evolution from a research and early clinical-stage company into a fully integrated biopharmaceutical organization focused on targeted protein degradation medicines. - Nurix's pipeline includes bexobrutideg (a BTK degrader co-developed with Roche), NX-1607 (a CBL-B inhibitor), and degraders of IRAK4 and STAT6 in collaboration with Gilead and Sanofi.
- Sanofi has dosed the first patient in a Phase 1 first-in-human trial of SAR448272, an oral small-molecule degrader targeting STAT6 for type 2 inflammatory diseases. - Nurix receives a $10 million milestone payment, bringing total proceeds from the 2019 Sanofi collaboration to approximately $139 million, with up to $453 million in remaining STAT6 milestones. - SAR448272 eliminates STAT6 protein rather than merely blocking its activity, offering a differentiated oral approach compared to injectable biologics like dupilumab. - Nurix retains a U.S. co-development and co-promotion option exercisable after clinical proof of concept, insulating its cash runway while preserving downstream value.
- Nurix Therapeutics is advancing NX-5948, an oral BTK degrader, in Phase 2 trials for relapsed/refractory B-cell malignancies and autoimmune diseases. - NX-2127, another oral BTK degrader, is being evaluated in Phase 1a/1b trials for relapsed or refractory B-cell malignancies. - The company is also developing NX-1607, an oral CBL-B inhibitor in Phase 1a/1b trials for immuno-oncology indications, and NX-0479/GS-6791, an IRAK4 degrader for rheumatoid arthritis. - Nurix holds strategic collaborations with Gilead Sciences, Sanofi, and Pfizer for co-development and co-commercialization of multiple drug candidates.
- Roche and Nurix Therapeutics signed an exclusive licensing and collaboration agreement valued at up to $2.3 billion focused on the blood cancer drug bexobrutideg. - Nurix will receive $700 million upfront, with additional potential payouts tied to development, regulatory, and sales milestones. - Bexobrutideg, a targeted protein degrader, is planned to enter a Phase III clinical trial for chronic lymphocytic leukemia (CLL) in the summer. - The companies will co-commercialize the drug in the U.S. with equal profit-and-loss sharing, while Roche will handle commercialization outside the U.S. and pay royalties to Nurix.
- Bexobrutideg, a BTK degrader, demonstrated an 83% objective response rate in the phase Ia dose-escalation portion of the NX-5948-301 trial in heavily pretreated R/R CLL/SLL patients at 22.4 months follow-up. - In phase Ib expansion cohorts, ORRs reached 92.9% in BTKi-exposed/BCL2i-naïve patients and 84.2% in BTKi-naïve or treatment-naïve patients, with lymph node reductions observed regardless of prior treatment. - The most common treatment-emergent adverse event was purpura/contusion; no dose-limiting toxicities were observed at any dose level, and grade ≥3 treatment-related TEAEs occurred in 24.6% of patients. - A phase II DAYBreak-201 study is ongoing, with a phase III DAYBreak-306 trial expected to initiate in 2026, supporting further clinical development of this first-in-class oral BTK degrader.
- Nurix Therapeutics appointed Roger Dansey, M.D., former Chief Development Officer and Chief Oncology Officer of Pfizer Oncology, to its board of directors. - Dr. Dansey brings over two decades of leadership experience in drug development and commercialization, having contributed to multiple breakthrough cancer medicine approvals. - The appointment comes as Nurix accelerates pivotal trials for its lead BTK degrader bexobrutideg in chronic lymphocytic leukemia. - Dr. Dansey's expertise in targeted protein degradation stems from his work at Seagen developing degrader antibody conjugates (DACs).
- Nurix Therapeutics reported Phase 1a data for NX-1607, a first-in-class oral CBL-B inhibitor, demonstrating a 49.3% disease control rate across 82 heavily pretreated patients with advanced solid tumors. - The drug showed notable activity in microsatellite stable colorectal cancer and prostate cancer, tumor types typically unresponsive to current immunotherapies, with one patient achieving a partial response lasting 27 months. - NX-1607 demonstrated dose-dependent immune activation and anti-tumor activity with a tolerable safety profile comparable to approved immuno-oncology agents, supporting expansion cohorts at higher doses. - The novel mechanism targets CBL-B, an E3 ligase that regulates multiple immune cell types beyond T cells, offering a distinct approach from PD-1/PD-L1 checkpoint inhibitors.
- Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies. - Phase 1a data presented at SOHO 2025 demonstrated bexobrutideg achieved an 80.9% objective response rate in 47 CLL patients, with rapid responses and durable activity across high-risk subgroups including those with TP53, PLCG2, and BTK mutations. - The BTK degrader showed strong efficacy in Waldenström macroglobulinemia with an 84.2% response rate in 19 patients, while maintaining a favorable safety profile with no dose-limiting toxicities or atrial fibrillation events. - Nurix reported $428.8 million in cash and marketable securities, providing financial runway as research and development expenses increased to $86.1 million in Q3 2025 to support accelerated clinical development.
- Nurix Therapeutics presented preclinical data for GS-6791, a novel IRAK4 protein degrader developed in collaboration with Gilead Sciences, demonstrating potent inhibition of IL-1 and IL-36 inflammatory pathways. - The oral degrader achieved near-complete IRAK4 knockdown in human blood and keratinocytes, showing significant disease reduction in a preclinical atopic dermatitis model. - A first-in-human Phase 1 trial in healthy volunteers is currently ongoing, with the FDA having cleared the IND application in April 2025. - The collaboration could yield up to $420 million in milestone payments for Nurix, with Gilead exercising its option to license the compound in March 2023.
- Nurix Therapeutics is advancing bexobrutideg (NX-5948), the first targeted protein degrader with the "DEG" stem designation, into Phase III clinical development for chronic lymphocytic leukemia treatment. - The company positions protein degraders as a revolutionary new class of therapeutics that represents a major evolution beyond traditional small molecule inhibitors and antibodies. - Nurix has disclosed new preclinical data supporting dose selection for bexobrutideg's registrational trials and provided first public data on partnered STAT6 and IRAK4 degrader programs. - The company's pipeline spans oncology and inflammation/immunology indications, with the STAT6 program partnered with Sanofi demonstrating the commercial potential of their degrader platform.
